Oxford BioTherapeutics

Join OBT's Arnima Bisht at the upcoming PEGS Boston Summit, May 13-17, 2024., where she will be addressing ground-breaking advancements in ADC development! Arnima, Senior Director of Preclinical & Translational Research, will be presenting on: ‘OBT076, an Innovative ADC with Dual MOA, Currently in Clinical Phase 1—The Mechanisms, ADC Design, Preclinical Activity, and Clinical Progress to Date’. Don't miss out on this exclusive opportunity to stay at the forefront of ADC innovation.! See you there! #PEGsConference #ADC #Innovation #CancerResearch #BioTherapeutics

We are thrilled to share milestone achievements for our business development team members Abbie Houghton and Somdatta Basu! Both Abbie and Somdatta earned the Impellus Level 3 Certificate of Learning in the Professional Sales Environment.    At OBT we support our staff with courses for their development, in this case with strategies to excel in the dynamic world of sales.   #SalesExcellence #ImpellusCertificate #BusinessDevelopment

Exciting News from Biologics 2024 Conference!   We are delighted to share that Christian Rohlff, our CEO, recently participated in an insightful post-event video from the Biologics 2024 Conference by Oxford Global.   Christian delves into key highlights, insights, and the latest advancements in biologics research to the future of therapeutic innovation in oncology.   #Biologics2024 #Biotech #Innovation #Leadership #PostEventInsights

We are celebrating our 20th anniversary!   Two decades ago, we embarked on a journey to pioneer oncology target discovery and therapeutics. We are proud of our efforts and the incredible team behind our success. "I would like to thank every member of our OBT team for their dedicated and integrated efforts. Together we have enabled OBT to deliver on our promise to develop novel treatments for those patients and tumor groups within specific cancer sub-types that are either unresponsive or marginally responsive to conventional treatments." Christian Rohlff, CEO, Oxford BioTherapeutics. We believe that we at OBT are uniquely positioned, now more than ever, both within the field of cancer therapeutics and at this important period in the timeline of immuno-oncology, to deliver and build on our commitment to cancer patients and their families. Here's to 20 years of progress, and to many more milestones ahead!

At Oxford BioTherapeutics, we prioritize the continual growth and development of our team members, recognizing that their proficiency directly impacts our ability to deliver exceptional programs. Join us in celebrating our Lab Managers, Jason Allen DipNEBOSH (UK) and Danielle Gomes (US) who have both achieved prestigious qualifications in health and safety in their respective countries. Danielle recently attained the OSHA 30 training course certification providing broad and in-depth, industry-specific training which is intended for supervisors and workers with safety and health responsibility. Jason has held the prestigious NEBOSH National Diploma in Occupational Health and Safety as well as the NEBOSH National General Certificate for a number of years. We look forward to supporting their continued success and contributions to the organization. #HealthAndSafety #ProfessionalDevelopment #TeamSuccess

Our Associate Director, Belinda Cairns, will be representing Oxford BioTherapeutics at the AACR Annual Meeting taking place, April 5-10, 2024 at the San Diego Convention Center.   Belinda will be showcasing her expertise as she presents her poster titled "Discovery and Identification of a Novel Cancer-Associated Fibroblast Target using Oxford BioTherapeutics' OGAP® Verify Discovery Platform,” at the Late-Breaking Research: Experimental and Molecular Therapeutics 4 session on Wednesday 10th of April between 9:00 am and 12:30 pm.   Be sure to join us at AACR to gain valuable insights from Belinda and other industry experts.   #AACRAnnualMeeting #CancerResearch #Networking #Innovation

Our Associate Director, Belinda Cairns, will be representing Oxford BioTherapeutics at the AACR Annual Meeting taking place, April 5-10, 2024 at the San Diego Convention Center.   Belinda will be showcasing her expertise as she presents her poster titled "Discovery and Identification of a Novel Cancer-Associated Fibroblast Target using Oxford BioTherapeutics' OGAP® Verify Discovery Platform,” at the Late-Breaking Research: Experimental and Molecular Therapeutics 4 session on Wednesday 10th of April between 9:00 am and 12:30 pm.   Be sure to join us at AACR to gain valuable insights from Belinda and other industry experts.   #AACRAnnualMeeting #CancerResearch #Networking #Innovation

The World ADC London conference is officially a wrap! Lindsey Hudson, Somdatta Basu, Abbie Houghton and Ben Thomas, represented the team announcing the launch of the innovative OGAP®-Verify target identification platform. Our discussions sparked interesting conversations, it was great to see the enthusiasm and interest in OGAP®-Verify and how it has the potential to improve outcomes for cancer patients. The conference provided us with a great opportunity to reconnect with familiar faces and create new connections. Thank you to everyone who came by the poster sessions and attended Ben’s presentation. If you missed a chance to stop by or would like to find out more click here: https://lnkd.in/eUqTZ6fE https://lnkd.in/eJHDVag8 https://lnkd.in/erHV6ySR #WADCLondon #CancerInnovation #ADCs

Join Lindsey Hudson, Senior Director of Business Development, and Business Development Associate, Abbie Houghton, at the BIO-EUROPE Springtime Partnering Event in Barcelona, Spain, 18-20 March. We are excited to connect with the global biopharma community to explore potential life science partnerships in oncology and antibody-based therapeutics. Please reach out on the BIO partnering platform if you will be attending and would like to meet to discuss potential collaboration. Find out more about the event:    #BIOEurope #Antibodydiscovery #Oncology #ADCs